



**HAL**  
open science

## **Plasma Levels of Advanced Glycation End Products are Associated with Hemolysis-related Organ Complications in Sickle Cell Patients**

Erfan Nur, D. P.M. Brandjes, John J. Schnog, Hans-Martin Otten, Karin Fijnvandraat, Casper G. Schalkwijk, Bart J Biemond

### ► **To cite this version:**

Erfan Nur, D. P.M. Brandjes, John J. Schnog, Hans-Martin Otten, Karin Fijnvandraat, et al.. Plasma Levels of Advanced Glycation End Products are Associated with Hemolysis-related Organ Complications in Sickle Cell Patients. *British Journal of Haematology*, 2010, 151 (1), pp.62. <10.1111/j.1365-2141.2010.08320.x>. <hal-00560772>

**HAL Id: hal-00560772**

**<https://hal.science/hal-00560772v1>**

Submitted on 30 Jan 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization



**Plasma Levels of Advanced Glycation End Products are  
Associated with Hemolysis-related Organ Complications in  
Sickle Cell Patients**

Journal:	<i>British Journal of Haematology</i>
Manuscript ID:	BJH-2010-00495.R2
Manuscript Type:	Ordinary Papers
Date Submitted by the Author:	26-May-2010
Complete List of Authors:	Nur, Erfan; Academic medical center, Hematology Brandjes, D.; Slotervaart Hospital, Dept. of Internal Medicine Schnog, John; Sint Elisabeth Hospital, Dept. of Haematology/Oncology Otten, Hans-Martin; Slotervaart Hospital, Internal Medicine Fijnvandraat, Karin; Emma Children's Hospital, Academic Medical Centre, Department of Paediatric Clinical Epidemiology Schalkwijk, Casper; Academic Hospital Maastricht, Laboratory for Metabolism and Vascular Medicine Biemond, Bart; Academic Medical Centre Amsterdam, Dept. of Haematology
Key Words:	SICKLE CELL DISEASE, hemolysis, OXIDATIVE STRESS, advanced glycation end products, organ damage

# Plasma Levels of Advanced Glycation End Products are Associated with Haemolysis-related Organ Complications in Sickle Cell Patients

Erfan Nur<sup>1,2</sup>, Dees P. Brandjes<sup>1</sup>, John-John B. Schnog<sup>1,3</sup>, Hans-Martin Otten<sup>1</sup>, Karin Fijnvandraat<sup>4</sup>, Casper G. Schalkwijk<sup>5</sup> and Bart J. Biemond<sup>2</sup>; the CURAMA Study Group\*

Dept. of Internal Medicine, Slotervaart Hospital<sup>1</sup>, Amsterdam, The Netherlands;  
Depts. of Haematology<sup>2</sup> and Paediatric Haematology<sup>4</sup>, Academic Medical Centre, Amsterdam, The Netherlands; Dept. of Haematology/Medical Oncology, Sint Elisabeth Hospital<sup>3</sup>, Curaçao, Netherlands Antilles; Department of Internal Medicine, Laboratory for Metabolism and Vascular Medicine, Academic Hospital Maastricht<sup>5</sup>, Maastricht, The Netherlands

\* The CURAMA study group is a collaborative effort studying sickle cell disease in the Netherlands Antilles and the Netherlands. Participating centres: The Red Cross Blood Bank Foundation, Curaçao, Netherlands Antilles; The Antillean Institute for Health Research, Curaçao, Netherlands Antilles, The Department of Internal Medicine, Slotervaart Hospital, Amsterdam, the Netherlands; the Department of Vascular Medicine and the Department of Haematology, Academic Medical Centre, Amsterdam, the Netherlands; the Department of Haematology, Erasmus Medical Centre, Rotterdam, the Netherlands; the Department of Pathology and Laboratory Medicine, Groningen University Hospital, the Netherlands; the Department of Internal Medicine, the Laboratory of Clinical Thrombosis and Haemostasis, and the Cardiovascular Research Institute, Academic Hospital Maastricht, the Netherlands.

Article title: plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients

Short title: AGEs are associated with organ complications in SCD

Word count abstract: 195

Word count manuscript: 2579

References: 49

Tables: 3

Figures: 2

## Corresponding author

Bart J. Biemond, MD, PhD

Academic Medical Centre, Department of Haematology, F4-224

PO box 22660

1100 DD Amsterdam

The Netherlands

Telephone: +31-20-5665785

Fax: +31-20-6919743

e-mail: [b.j.biemond@amc.uva.nl](mailto:b.j.biemond@amc.uva.nl)

## Summary

Oxidative stress plays an important role in the pathophysiology of sickle cell disease (SCD). Plasma levels of advanced glycation end products (AGEs) are increased under oxidative conditions and are associated with disease severity in diabetes and inflammatory diseases. We questioned whether AGEs are increased in sickle cell patients and whether they are associated with SCD related complications. Plasma levels of the AGEs pentosidine, N<sup>ε</sup>-(carboxymethyl)lysine (CML) and N<sup>ε</sup>-(carboxyethyl)lysine (CEL) were measured using single-column high performance liquid chromatography with fluorescence detection (pentosidine) and ultra performance liquid chromatography-tandem mass spectrometry (CML and CEL). Plasma levels of pentosidine and CML were increased in HbSS/HbSβ<sup>0</sup>-thalassaemia (n=60) and HbSC/HbSβ<sup>+</sup>-thalassaemia (n=42) patients during steady state as compared to healthy HbAA controls (n=30) without increments during painful crisis. CEL levels were comparable between all groups. Pentosidine and CML levels correlated significantly to haemolytic rate during the clinically asymptomatic state while pentosidine was significantly related to the number of haemolysis-related organ complications. The increased plasma AGE levels in sickle cell patients and their association with haemolysis and haemolysis-related complications suggest AGEs might be implicated in the pathophysiology of the haemolytic phenotype of SCD. Measurement of AGEs might be useful in predicting organ complications in SCD.

**Keyword:** sickle cell disease, advanced glycation end products, oxidative stress, haemolysis, organ damage

## Introduction

Sickle cell disease (SCD) is characterized by unstable auto-oxidative sickle haemoglobin (HbS) (Hebbel *et al*, 1988), chronic intravascular haemolysis (Reiter *et al*, 2002), recurrent ischemia reperfusion injury (Nath *et al*, 2005) and low grade inflammation (Akohe *et al*, 2007), all contributing to an increased generation of reactive oxygen species (ROS) potentially contributing to the characteristic widespread organ damage (van Beers *et al*, 2008).

ROS inflict direct oxidative damage to tissue by reacting with cellular proteins (interfering with their functions), membrane structures, DNA and extracellular matrix (Botto *et al*, 2002; Jain & Shohet, 1984; Rice-Evans *et al*, 1986). Oxidative stress also results in increased production and accumulation of advanced glycation end products (AGEs), which are not only well-established markers of oxidative stress (Koyama *et al*, 2007; Genuth *et al*, 2005; Gerrits *et al*, 2008), but are themselves oxidatively active and have been demonstrated to play a role in the pathophysiology of organ complications (nephropathy, retinopathy, neuropathy and ischemic heart disease) in diabetes and auto-immune inflammatory diseases (Ahmed, 2005; Lieu *et al*, 2004; Miyata *et al*, 1998; Beisswenger *et al*, 1995).

AGEs are generated by non-enzymatic glycation and oxidation of proteins, lipids and nuclear acids in the Maillard reaction (Ahmed, 2005). AGEs are associated with several pathological mechanisms which could contribute to organ damage and disease severity. Cross-linking of AGEs with intra- and extracellular proteins affects their conformational structure resulting in distortion of normal tissue architecture (Goldin *et al*, 2006). This is especially important in the cardiovascular system where thickening of the basement membrane and reduced elasticity in blood vessels cause reduced filtration rate across the vessel lumen and diminished arteriolar vasodilatory capacity (Goldin *et al*, 2006; Greenwald, 2007; Aronson, 2003). Another mechanism, through which AGEs inhibit vasodilatation, is by inducing resistance to nitric oxide and suppressing nitric oxide synthesis (Soro-Paavonen *et*

1  
2  
3 al, 2010). Furthermore, the interaction of AGEs with their receptor RAGE, which is expressed  
4 on different cells including endothelial cells and macrophages, enhances the production and  
5 expression of pro-inflammatory cytokines, adhesion molecules and oxidants (Ahmed,  
6 2005; Brett *et al*, 1993; Pertynska-Marczewska *et al*, 2004; Liu *et al*, 2009). In diabetes, AGEs  
7 have been shown to increase vascular permeability (Hirose *et al*, 2010) which is a major and  
8 early characteristic of diabetic vasculopathy (Viberti, 1983). AGEs are also known to induce  
9 apoptosis in different cell types and thereby play a significant role in the pathology of various  
10 diseases and organ complications (Yamagishi *et al*, 2002; Lim *et al*, 2008; Sekido *et al*, 2004).  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 A recent study showed elevated plasma levels of AGEs in paediatric sickle cell patients  
23 during the clinically asymptomatic state without further increments during painful crisis  
24 (Somjee *et al*, 2005). However, patients with macrovascular (cerebrovascular accidents or  
25 abnormal transcranial Doppler study) or microvascular (evidence of retinopathy or  
26 nephropathy) SCD related organ complications were excluded from this study. As oxidative  
27 stress is associated with both acute and chronic organ complications in sickle cell patients  
28 (Klings & Farber, 2001; Morris *et al*, 2008; Fibach & Rachmilewitz, 2008), we studied  
29 whether AGEs are elevated in adult sickle cell patients and whether they are associated with  
30 SCD related organ complications.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

## 48 **Patients and methods**

### 49 *Study population*

50  
51 Adult sickle cell patients ( $\geq 18$  years), including sickle cell anaemia (HbSS) and compound  
52 heterozygous states sickle  $\beta^0$ -thalassaemia (HbS $\beta^0$ -thal), sickle  $\beta^+$ -thalassaemia (HbS $\beta^+$ -thal)  
53 and sickle haemoglobin C disease (HbSC) visiting the out-patient clinic during the clinically  
54 asymptomatic state (defined as being free of SCD related acute events, such as painful crisis,  
55  
56  
57  
58  
59  
60

1  
2  
3 priapism, acute chest syndrome, strokes, sequestration crises and infections during at least 4  
4  
5 months prior to study participation) and patients admitted for a painful crisis (defined as  
6  
7 musculo-skeletal pain not otherwise explained and recognized as such by the patient) at the  
8  
9 Academic Medical Centre and Slotervaart Hospital, Amsterdam, The Netherlands were  
10  
11 eligible for the study. Exclusion criteria were: diabetes mellitus, renal failure, auto-immune  
12  
13 inflammatory diseases, active infection and pregnancy. Healthy race matched volunteers with  
14  
15 normal haemoglobin (HbAA) served as controls. Haemoglobin (Hb) types were confirmed in  
16  
17 all participants by high performance liquid chromatography (HPLC). All participants received  
18  
19 verbal and written explanation of the study and subsequently gave written informed consent.  
20  
21 The protocol was reviewed and approved by the local medical ethical committee and  
22  
23 conducted in agreement with the Helsinki declaration of 2000.  
24  
25  
26  
27  
28  
29  
30  
31

### 32 *Blood sample Collection*

33  
34 Blood from patients was obtained upon their visit to the outpatient clinic or their presentation  
35  
36 at the emergency department. Standard blood counts were performed in EDTA-anticoagulated  
37  
38 blood (Cell-Dyn 4000, Abbott, Illinois, USA). Lactate dehydrogenase (LDH) and bilirubin  
39  
40 levels were measured in heparinized plasma with spectrophotometry (P800 Modular, Roche,  
41  
42 Basel, Switzerland). Blood samples were centrifuged within 30 minutes of withdrawal at 3000  
43  
44 rpm (4 °C) for 15 minutes and serum and plasma samples were stored at -80°C until further  
45  
46 analysis.  
47  
48  
49  
50  
51  
52

### 53 *Laboratory analysis*

54  
55 The AGEs (pentosidine, N<sup>ε</sup>-(carboxymethyl)lysine (CML) and N<sup>ε</sup>-(carboxyethyl)lysine  
56  
57 (CEL)) were measured in EDTA anti-coagulated plasma. Pentosidine was measured with  
58  
59 single-column HPLC with fluorescence detection and CML and CEL were determined by  
60

1  
2  
3 ultra performance liquid chromatography-tandem mass spectrometry as described previously  
4  
5 (Scheijen *et al*, 2009;Teerlink *et al*, 2004). Inter-assay coefficients of variation were 4.9% for  
6  
7 pentosidine, 3.7% for CML and 5.1% for CEL. The intra-assay coefficients of variation were  
8  
9 below 4% for all these AGEs. Soluble vascular cell adhesion molecule-1 (sVCAM-1) levels  
10  
11 were determined in serum using enzyme-linked immunosorbent assay (ELISA; R&D  
12  
13 Systems, Minneapolis, MN, USA). Plasma levels of von Willebrand Factor antigen (vWF:Ag)  
14  
15 were determined in citrate plasma using a homemade ELISA.  
16  
17  
18  
19

### 20 21 22 *Data analysis*

23  
24 For data analysis, patients were classified according to genotype into two groups: patients  
25  
26 with the relatively severe genotypes HbSS and HbS $\beta^0$ -thal grouped in one group  
27  
28 (HbSS/HbS $\beta^0$ -thal) and patients with the relatively milder HbSC and HbS $\beta^+$ -thal genotypes  
29  
30 collected in the other group (HbSC/HbS $\beta^+$ -thal) (Powars *et al*, 2002). SCD related organ  
31  
32 complications were grouped as haemolysis related (pulmonary hypertension, leg ulcers,  
33  
34 priapism, ischemic stroke, cholecystolithiasis and microalbuminuria) or viscosity-vaso-  
35  
36 occlusion related (acute painful crisis, acute chest syndrome, retinopathy and avascular  
37  
38 necrosis of bone) complications (Kato *et al*, 2007).  
39  
40  
41  
42  
43  
44  
45

### 46 47 *Statistical analysis*

48  
49 As data were not normally distributed, statistical tests for nonparametric data were used. For  
50  
51 multiple group comparisons of continuous variables the Kruskal–Wallis test was employed.  
52  
53 The Mann–Whitney U-test was used for comparison between two groups. The Wilcoxon  
54  
55 Signed Rank Test was used for a paired analysis of patients who were included both during  
56  
57 asymptomatic state and painful crisis. For correlation studies, the Spearman Rank correlation  
58  
59 coefficient ( $r_s$ ) was determined. To analyze the association of plasma AGEs with haemolysis  
60

1  
2  
3 and fetal Hb (HbF), a multivariate stepwise regression model with forward entry and removal  
4  
5 was constructed with one of the AGEs as the dependent variable and group (healthy control,  
6  
7 patient during steady state or painful crisis), age, Hb, reticulocyte counts, LDH, total bilirubin  
8  
9 and HbF as the independent variables.  $P < 0.05$  was considered statistically significant (SPSS  
10  
11 16.0, Chicago, IL, USA).  
12  
13  
14  
15  
16  
17  
18  
19

## 20 Results

21  
22 Sixty HbSS/HbS $\beta^0$ -thal patients (54 HbSS, 6 HbS $\beta^0$ -thal) and 42 HbSC/HbS $\beta^+$ -thal (32 HbSC,  
23  
24 10 HbS $\beta^+$ -thal) were included during the asymptomatic state and 27 HbSS/HbS $\beta^0$ -thal  
25  
26 patients (25 HbSS, 2 HbS $\beta^0$ -thal) and 8 HbSC/HbS $\beta^+$ -thal patients (6 HbSC, 2 HbS $\beta^+$ -thal)  
27  
28 were included during acute painful crisis. Thirty healthy race matched HbAA volunteers  
29  
30 served as controls. Table 1 shows clinical and biochemical characteristics of the participants.  
31  
32  
33

34 Plasma levels of pentosidine were significantly higher in asymptomatic state  
35  
36 HbSS/HbS $\beta^0$ -thal ( $P < 0.0001$ ) and HbSC/HbS $\beta^+$ -thal patients ( $P = 0.002$ ) than in healthy  
37  
38 controls but did not increase further during painful crisis (Figure 1A). CML levels were  
39  
40 significantly higher in asymptomatic state HbSS/HbS $\beta^0$ -thal patients as compared to controls  
41  
42 ( $P = 0.007$ ; Figure 1B) but were comparable between controls and asymptomatic state  
43  
44 HbSC/HbS $\beta^+$ -thal patients. No further increases in CML levels were observed during painful  
45  
46 crisis. Also in a paired analysis of 25 patients included both during asymptomatic state and  
47  
48 painful crisis, there were no increases in plasma levels of pentosidine and CML during painful  
49  
50 crisis (data not shown). CEL levels were comparable between controls and patients during  
51  
52 both asymptomatic state and painful crisis (Figure 1C).  
53  
54  
55  
56

57 Pentosidine and CML levels were higher in sickle cell patients with 1, 2 and 3 or 4  
58  
59 haemolysis-related organ complications than in patients without these complications (Figures  
60

1  
2  
3 2A and 2C). Also when dividing the patients into 2 groups of patients with at least one  
4  
5 haemolysis-related complication versus patients without these complications, pentosidine and  
6  
7 CML levels were higher in the former group (Figures 2B and 2D). As haemolysis is more  
8  
9 severe in HbSS/HbS $\beta^0$ -thal patients and there were more patients in the relatively milder  
10  
11 HbSC/HbS $\beta^+$ -thal patients who were not tested for all listed organ complications, we also  
12  
13 analyzed the differences in pentosidine and CML levels in the HbSS/HbS $\beta^0$ -thal group alone,  
14  
15 where the differences between patients with and those without haemolysis-related  
16  
17 complications were more pronounced (Figures 2B and 2D). AGEs were not associated with  
18  
19 viscosity-vaso-occlusion related organ complications (data not shown).  
20  
21  
22  
23

24  
25 In a sub-analysis of the 60 HbSS/HbS $\beta^0$  patients, pentosidine and CML concentrations  
26  
27 were significantly related to haemolytic rate (Table 2). Plasma concentrations of pentosidine  
28  
29 and CML were also inversely related to HbF% (Table 2). In a multivariate stepwise regression  
30  
31 analysis, adjusting for age, group, HbF and the markers of haemolytic anaemia, only LDH  
32  
33 was significantly related to both pentosidine (0.55 x LDH;  $P < 0.0001$ ) and CML (0.35 x  
34  
35 LDH;  $P < 0.0001$ ).  
36  
37

38  
39 Both pentosidine and CML levels were significantly related to sVCAM-1 levels in  
40  
41 HbSS/HbS $\beta^0$ -thal patients during asymptomatic state. During painful crisis the correlation  
42  
43 between AGEs and sVCAM-1 was stronger than during the asymptomatic state (Table 3).  
44  
45 Pentosidine levels in asymptomatic state patients also correlated with plasma levels of  
46  
47 vWF:Ag (Table 3).  
48  
49

50  
51 The measured AGEs did not correlate with age or BMI in sickle cell patients (data not  
52  
53 shown). In controls, only pentosidine levels were related to age ( $Sr = 0.49$ ,  $P = 0.006$ ).  
54

55 Nineteen patients during asymptomatic state (16 HbSS/HbS $\beta^0$ -thal and 3 HbSC/HbS $\beta^+$ -thal)  
56  
57 and 8 patients during painful crisis (5 HbSS/HbS $\beta^0$ -thal and 3 HbSC/HbS $\beta^+$ -thal) were on  
58  
59 hydroxyurea therapy. AGE levels were not different between patients with and those without  
60

1  
2  
3 hydroxyurea therapy (data not shown). As AGEs are cleared by the kidneys, we analysed  
4 correlations between AGEs and plasma creatinine as a biomarker of renal function. However,  
5  
6 AGEs were not related to creatinine levels in both controls and sickle cell patients (data not  
7  
8 shown).  
9  
10  
11  
12  
13  
14  
15  
16

## 17 **Discussion**

18  
19  
20 In the current study, plasma levels of the AGEs pentosidine and CML, which are established  
21  
22 biomarkers of oxidative stress, were higher in clinically asymptomatic sickle cell patients as  
23  
24 compared to healthy controls, without further increments during painful crisis. These findings  
25  
26 confirm the observations by Somjee et al, who found increased levels of AGEs in children  
27  
28 with SCD without further increases during painful crisis (Somjee et al, 2005). In our study,  
29  
30 we measured three different AGEs with specific analytical techniques and pentosidine and  
31  
32 CML, but not CEL, were significantly related to the haemolytic rate and accordingly  
33  
34 significantly associated with endothelial activation as reflected by sVCAM-1 and vWF;Ag  
35  
36 levels and with the presence of haemolysis related organ damage. These data suggest that  
37  
38 AGEs may play an important role in the pathophysiology of chronic haemolysis associated  
39  
40 organ complications but not of viscosity-vaso-occlusion associated complications in SCD  
41  
42 (Kato et al, 2005;Landburg et al, 2010). However, further studies are needed to elucidate the  
43  
44 mechanistic contributions of AGEs to haemolysis related organ complications in SCD.  
45  
46  
47  
48  
49

50  
51 Due to continuous intravascular haemolysis, sickle cell patients have highly increased  
52  
53 plasma levels of cell-free haem. The hydrophobic haem rapidly intercalates into the plasma  
54  
55 membrane of (endothelial) cells where it releases its iron (Jeney et al, 2002), which  
56  
57 potentiates endothelial cell activation and damage by catalyzing non-enzymatic generation of  
58  
59 ROS and AGEs (Jeney et al, 2002;Galaris & Pantopoulos, 2008). Indeed, several studies have  
60

1  
2  
3 shown an association between haemolytic rate and endothelial activation in SCD (Schnog *et*  
4 *al*, 2003;Kato *et al*, 2006), which could, at least in part, be explained by the haemolysis driven  
5  
6 production of AGEs. In line with this observation, serum levels of sVCAM-1 correlated with  
7  
8 plasma levels of pentosidine and CML. Also a possible ameliorating effect of HbF on  
9  
10 oxidative stress, through both lower percentage of the auto-oxidative HbS and reduced  
11  
12 haemolysis, is suggested by the inverse correlations of pentosidine and CML with HbF  
13  
14 (Hebbel *et al*, 1988). Total glutathione and its reduced form (GSH), a major intracellular  
15  
16 antioxidant, have been reported to be decreased in sickle cell patients (Tatum & Chow,  
17  
18 1996;Wetterstroem *et al*, 1984). Somjee et al (2005) reported a strong inverse correlation  
19  
20 between plasma AGEs and GSH levels in sickle erythrocytes. This might suggest that  
21  
22 increased production of ROS and AGEs, mainly due to the auto-oxidative HbS, causes  
23  
24 excessive consumption of the intracellular antioxidants rendering the erythrocytes more  
25  
26 susceptible to oxidative damage. On the other hand, reduced GSH may be a rate-limiting  
27  
28 factor in the increased formation of AGEs since GSH is an essential cofactor for glyoxalase  
29  
30 1, the enzyme that efficiently detoxifies the major AGE precursor methylglyoxal to S-d-  
31  
32 lactoyl-gluthathione (Brouwers *et al*, 2010).  
33  
34  
35  
36  
37  
38  
39  
40

41 While AGEs in the study patients were increased during the clinically asymptomatic state,  
42  
43 no further increments were detected during painful crises, suggesting that factors contributing  
44  
45 to local vaso-occlusive painful crisis with potential ischemia-reperfusion injury have no  
46  
47 significant effect on plasma levels of AGEs. This observation confirms findings by earlier  
48  
49 studies which also did not detect further increases in AGEs (Somjee *et al*, 2005) and  
50  
51 isoprostanes (another marker of oxidative stress) (Klings *et al*, 2001) during painful crisis.  
52  
53  
54 This is confirmed by the fact that pentosidine and CML correlated only with haemolysis-  
55  
56 related organ complications and not with viscosity-vaso-occlusion related complications.  
57  
58  
59  
60 AGEs may therefore potentially be useful as biomarkers of haemolysis related complications

1  
2  
3 in the long term follow-up of sickle cell patients. AGEs are produced within hours, are cleared  
4  
5 by the kidneys and most plasma AGEs are irreversibly bound to serum albumin, which has a  
6  
7 half-life of approximately 20 days (Jones *et al*, 1983). Therefore, AGE half-life is not likely to  
8  
9 have affected our results during painful crisis.  
10  
11

12 The correlations between AGEs and markers of endothelial activation (sVCAM-1 and  
13  
14 vWF:Ag) suggest that AGEs might be implicated in endothelial damage, both via  
15  
16 accumulation in vascular wall and activation of RAGE (Ahmed, 2005). Interestingly, during  
17  
18 painful crisis, without further increments in AGEs, the correlations of pentosidine and CML  
19  
20 with sVCAM-1 were stronger than in asymptomatic state. While the exact mechanism for this  
21  
22 enhancing effect of painful crisis on the relationship between AGEs and endothelial activation  
23  
24 needs to be studied further, one possible explanation is an up-regulating effect of increased  
25  
26 inflammation during painful crisis on endothelial expression of RAGE (van Beijnum *et al*,  
27  
28 2008; Fiuza *et al*, 2003). Potential increased endothelial expression of RAGE during painful  
29  
30 crisis could amplify effects of AGEs on endothelial activation.  
31  
32  
33  
34  
35

36 In contrast to pentosidine and CML, plasma levels of CEL were not different between  
37  
38 controls and sickle cell patients. This might be explained by the fact that unlike pentosidine  
39  
40 and CML, production of CEL, via modifications of proteins by methylglyoxal, is highly  
41  
42 dependent on hyperglycemia (Ahmed *et al*, 1997), which is rare in SCD.  
43  
44

45 Since AGEs were strongly related to LDH on multivariate regression analysis, one might  
46  
47 question whether AGEs are just a biomarker of haemolytic rate in SCD. However, while  
48  
49 AGEs seem primarily to be downstream products of the excessive intravascular haemolysis in  
50  
51 SCD, given the strong evidence about their role in pathophysiology of (organ complications  
52  
53 in) other disease states, AGEs most likely have additional role in the pathophysiology and  
54  
55 disease severity of SCD.  
56  
57  
58  
59  
60

1  
2  
3 In conclusion, plasma levels of pentosidine and CML are increased and associated with  
4 haemolysis and haemolysis-related organ complications in sickle cell patients, suggesting that  
5 AGEs might be implicated in vascular damage and chronic organ complications in SCD.  
6  
7  
8  
9  
10 Measurement of these AGEs might be useful in assessing disease severity and predicting  
11  
12 organ complications in SCD.  
13  
14  
15  
16  
17  
18  
19

### 20 **Acknowledgements**

21  
22 This work was supported by grants from the Slotervaart Hospital Fund for Clinical Research  
23  
24 (Stichting Klinisch Wetenschappelijk onderzoek Slotervaart Ziekenhuis) (E.N.).  
25  
26  
27  
28

### 29 **Authorship Contributions**

30  
31 E.N. designed and performed research, analysed data and wrote the manuscript; D.P.B.,  
32  
33 H.M.O. and K.F critically reviewed and edited the manuscript, C.G.S. analysed data and  
34  
35 edited the manuscript, J.J.B.S. and B.J.B. designed research, participated in data analyses and  
36  
37 in writing the manuscript.  
38  
39  
40  
41  
42

### 43 **Conflict of Interest Disclosure**

44  
45 All authors declare no conflicts of interest.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

- 1  
2  
3  
4  
5  
6  
7  
8 Ahmed,M.U., Brinkmann,F.E., Degenhardt,T.P., Thorpe,S.R., & Baynes,J.W. (1997) N-  
9 epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by  
10 methylglyoxal, increases with age in human lens proteins. *Biochem.J.*, **324** ( Pt 2),  
11 565-570.  
12  
13  
14 Ahmed,N. (2005) Advanced glycation endproducts--role in pathology of diabetic  
15 complications. *Diabetes Res.Clin.Pract.*, **67**, 3-21.  
16  
17 Akohoue,S.A., Shankar,S., Milne,G.L., Morrow,J., Chen,K.Y., Ajayi,W.U., &  
18 Buchowski,M.S. (2007) Energy expenditure, inflammation, and oxidative stress in  
19 steady-state adolescents with sickle cell anemia. *Pediatr.Res.*, **61**, 233-238.  
20  
21  
22 Aronson,D. (2003) Cross-linking of glycated collagen in the pathogenesis of arterial and  
23 myocardial stiffening of aging and diabetes. *J.Hypertens.*, **21**, 3-12.  
24  
25 Beisswenger,P.J., Makita,Z., Curphey,T.J., Moore,L.L., Jean,S., Brinck-Johnsen,T., Bucala,R.,  
26 & Vlassara,H. (1995) Formation of immunochemical advanced glycosylation end  
27 products precedes and correlates with early manifestations of renal and retinal disease  
28 in diabetes. *Diabetes*, **44**, 824-829.  
29  
30  
31 Botto,N., Masetti,S., Petrozzi,L., Vassalle,C., Manfredi,S., Biagini,A., & Andreassi,M.G.  
32 (2002) Elevated levels of oxidative DNA damage in patients with coronary artery  
33 disease. *Coron.Artery Dis.*, **13**, 269-274.  
34  
35  
36 Brett,J., Schmidt,A.M., Yan,S.D., Zou,Y.S., Weidman,E., Pinsky,D., Nowygrod,R.,  
37 Neeper,M., Przysiecki,C., Shaw,A., & . (1993) Survey of the distribution of a newly  
38 characterized receptor for advanced glycation end products in tissues. *Am.J.Pathol.*,  
39 **143**, 1699-1712.  
40  
41  
42 Brouwers,O., Niessen,P.M., Haenen,G., Miyata,T., Brownlee,M., Stehouwer,C.D., De  
43 Mey,J.G., & Schalkwijk,C.G. (2010) Hyperglycaemia-induced impairment of  
44 endothelium-dependent vasorelaxation in rat mesenteric arteries is mediated by  
45 intracellular methylglyoxal levels in a pathway dependent on oxidative stress.  
46 *Diabetologia*, **53**, 989-1000.  
47  
48  
49 Fibach,E. & Rachmilewitz,E. (2008) The role of oxidative stress in hemolytic anemia.  
50 *Curr.Mol.Med.*, **8**, 609-619.  
51  
52  
53 Fiuza,C., Bustin,M., Talwar,S., Tropea,M., Gerstenberger,E., Shelhamer,J.H., &  
54 Suffredini,A.F. (2003) Inflammation-promoting activity of HMGB1 on human  
55 microvascular endothelial cells. *Blood*, **101**, 2652-2660.  
56  
57  
58 Galaris,D. & Pantopoulos,K. (2008) Oxidative stress and iron homeostasis: mechanistic and  
59 health aspects. *Crit Rev.Clin.Lab Sci.*, **45**, 1-23.  
60  
61  
62 Genuth,S., Sun,W., Cleary,P., Sell,D.R., Dahms,W., Malone,J., Sivitz,W., & Monnier,V.M.  
(2005) Glycation and carboxymethyllysine levels in skin collagen predict the risk of  
future 10-year progression of diabetic retinopathy and nephropathy in the diabetes

1  
2  
3 control and complications trial and epidemiology of diabetes interventions and  
4 complications participants with type 1 diabetes. *Diabetes*, **54**, 3103-3111.

5  
6  
7 Gerrits,E.G., Lutgers,H.L., Kleefstra,N., Graaff,R., Groenier,K.H., Smit,A.J., Gans,R.O., &  
8 Bilo,H.J. (2008) Skin autofluorescence: a tool to identify type 2 diabetic patients at  
9 risk for developing microvascular complications. *Diabetes Care*, **31**, 517-521.

10  
11 Goldin,A., Beckman,J.A., Schmidt,A.M., & Creager,M.A. (2006) Advanced glycation end  
12 products: sparking the development of diabetic vascular injury. *Circulation*, **114**, 597-  
13 605.

14  
15  
16 Greenwald,S.E. (2007) Ageing of the conduit arteries. *J.Pathol.*, **211**, 157-172.

17  
18 Hebbel,R.P., Morgan,W.T., Eaton,J.W., & Hedlund,B.E. (1988) Accelerated autoxidation and  
19 heme loss due to instability of sickle hemoglobin. *Proc.Natl.Acad.Sci.U.S.A.*, **85**, 237-  
20 241.

21  
22  
23 Hirose,A., Tanikawa,T., Mori,H., Okada,Y., & Tanaka,Y. (2010) Advanced glycation end  
24 products increase endothelial permeability through the RAGE/Rho signaling pathway.  
25 *FEBS Lett.*, **584**, 61-66.

26  
27 Jain,S.K. & Shohet,S.B. (1984) A novel phospholipid in irreversibly sickled cells: evidence  
28 for in vivo peroxidative membrane damage in sickle cell disease. *Blood.*, **63**, 362-367.

29  
30 Jeney,V., Balla,J., Yachie,A., Varga,Z., Vercellotti,G.M., Eaton,J.W., & Balla,G. (2002) Pro-  
31 oxidant and cytotoxic effects of circulating heme. *Blood*, **100**, 879-887.

32  
33  
34 Jones,I.R., Owens,D.R., Williams,S., Ryder,R.E., Birtwell,A.J., Jones,M.K., Gicheru,K., &  
35 Hayes,T.M. (1983) Glycosylated serum albumin: an intermediate index of diabetic  
36 control. *Diabetes Care*, **6**, 501-503.

37  
38 Kato,G.J., Gladwin,M.T., & Steinberg,M.H. (2007) Deconstructing sickle cell disease:  
39 reappraisal of the role of hemolysis in the development of clinical subphenotypes.  
40 *Blood Rev.*, **21**, 37-47.

41  
42  
43 Kato,G.J., Martyr,S., Blackwelder,W.C., Nichols,J.S., Coles,W.A., Hunter,L.A.,  
44 Brennan,M.L., Hazen,S.L., & Gladwin,M.T. (2005) Levels of soluble endothelium-  
45 derived adhesion molecules in patients with sickle cell disease are associated with  
46 pulmonary hypertension, organ dysfunction, and mortality. *Br.J.Haematol.*, **130**, 943-  
47 953.

48  
49  
50 Kato,G.J., McGowan,V., Machado,R.F., Little,J.A., Taylor,J., Morris,C.R., Nichols,J.S.,  
51 Wang,X., Poljakovic,M., Morris,S.M., Jr., & Gladwin,M.T. (2006) Lactate  
52 dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance,  
53 priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell  
54 disease. *Blood.*, **107**, 2279-2285.

55  
56  
57 Klings,E.S., Christman,B.W., McClung,J., Stucchi,A.F., McMahan,L., Brauer,M., &  
58 Farber,H.W. (2001) Increased F2 isoprostanes in the acute chest syndrome of sickle  
59 cell disease as a marker of oxidative stress. *Am.J.Respir.Crit Care Med.*, **164**, 1248-  
60 1252.

- 1  
2  
3 Klings,E.S. & Farber,H.W. (2001) Role of free radicals in the pathogenesis of acute chest  
4 syndrome in sickle cell disease. *Respir.Res.*, **2**, 280-285.  
5  
6  
7 Koyama,Y., Takeishi,Y., Arimoto,T., Niizeki,T., Shishido,T., Takahashi,H., Nozaki,N.,  
8 Hirono,O., Tsunoda,Y., Nitobe,J., Watanabe,T., & Kubota,I. (2007) High serum level  
9 of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients  
10 with heart failure. *J.Card Fail.*, **13**, 199-206.  
11  
12 Landburg,P.P., Teerlink,T., Biemond,B.J., Brandjes,D.P., Muskiet,F.A., Duits,A.J., &  
13 Schnog,J.B. (2010) Plasma asymmetric dimethylarginine concentrations in sickle cell  
14 disease are related to the hemolytic phenotype. *Blood Cells Mol.Dis.*  
15  
16  
17 Liew,A.F.M., van,H., V, Teerlink,T., Barto,R., Twisk,J., Stehouwer,C.D., & Schalkwijk,C.G.  
18 (2004) Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-  
19 (carboxyethyl)lysine in type 1 diabetic patients with impaired renal function:  
20 correlation with markers of endothelial dysfunction. *Nephrol.Dial.Transplant.*, **19**,  
21 631-636.  
22  
23  
24 Lim,M., Park,L., Shin,G., Hong,H., Kang,I., & Park,Y. (2008) Induction of apoptosis of Beta  
25 cells of the pancreas by advanced glycation end-products, important mediators of  
26 chronic complications of diabetes mellitus. *Ann.N.Y.Acad.Sci.*, **1150**, 311-315.  
27  
28  
29 Liu,J., Zhao,S., Tang,J., Li,Z., Zhong,T., Liu,Y., Chen,D., Zhao,M., Li,Y., Gong,X., Deng,P.,  
30 Wang,J.H., & Jiang,Y. (2009) Advanced glycation end products and  
31 lipopolysaccharide synergistically stimulate proinflammatory cytokine/chemokine  
32 production in endothelial cells via activation of both mitogen-activated protein kinases  
33 and nuclear factor-kappaB. *FEBS J.*, **276**, 4598-4606.  
34  
35  
36 Miyata,T., Ishiguro,N., Yasuda,Y., Ito,T., Nangaku,M., Iwata,H., & Kurokawa,K. (1998)  
37 Increased pentosidine, an advanced glycation end product, in plasma and synovial  
38 fluid from patients with rheumatoid arthritis and its relation with inflammatory  
39 markers. *Biochem.Biophys.Res.Comm.*, **244**, 45-49.  
40  
41  
42 Morris,C.R., Suh,J.H., Hagar,W., Larkin,S., Bland,D.A., Steinberg,M.H., Vichinsky,E.P.,  
43 Shigenaga,M., Ames,B., Kuypers,F.A., & Klings,E.S. (2008) Erythrocyte glutamine  
44 depletion, altered redox environment, and pulmonary hypertension in sickle cell  
45 disease. *Blood.*, **111**, 402-410.  
46  
47  
48 Nath,K.A., Grande,J.P., Croatt,A.J., Frank,E., Caplice,N.M., Hebbel,R.P., & Katusic,Z.S.  
49 (2005) Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion  
50 injury. *Am.J.Pathol.*, **166**, 963-972.  
51  
52  
53 Pertynska-Marczewska,M., Kiriakidis,S., Wait,R., Beech,J., Feldmann,M., & Paleolog,E.M.  
54 (2004) Advanced glycation end products upregulate angiogenic and pro-inflammatory  
55 cytokine production in human monocyte/macrophages. *Cytokine*, **28**, 35-47.  
56  
57  
58 Powars,D.R., Hiti,A., Ramicone,E., Johnson,C., & Chan,L. (2002) Outcome in hemoglobin  
59 SC disease: a four-decade observational study of clinical, hematologic, and genetic  
60 factors. *Am.J.Hematol.*, **70**, 206-215.

- 1  
2  
3 Reiter,C.D., Wang,X., Tanus-Santos,J.E., Hogg,N., Cannon,R.O., III, Schechter,A.N., &  
4 Gladwin,M.T. (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle-  
5 cell disease. *Nat.Med.*, **8**, 1383-1389.  
6  
7  
8 Rice-Evans,C., Omorphos,S.C., & Baysal,E. (1986) Sickle cell membranes and oxidative  
9 damage. *Biochem.J.*, **237**, 265-269.  
10  
11 Scheijen,J.L., van de Waarenburg,M.P., Stehouwer,C.D., & Schalkwijk,C.G. (2009)  
12 Measurement of pentosidine in human plasma protein by a single-column high-  
13 performance liquid chromatography method with fluorescence detection.  
14 *J.Chromatogr.B Analyt.Technol.Biomed.Life Sci.*, **877**, 610-614.  
15  
16  
17 Schnog,J.B., Rojer,R.A., Mac Gillavry,M.R., ten,C.H., Brandjes,D.P., & Duits,A.J. (2003)  
18 Steady-state sVCAM-1 serum levels in adults with sickle cell disease. *Ann.Hematol.*,  
19 **82**, 109-113.  
20  
21 Sekido,H., Suzuki,T., Jomori,T., Takeuchi,M., Yabe-Nishimura,C., & Yagihashi,S. (2004)  
22 Reduced cell replication and induction of apoptosis by advanced glycation end  
23 products in rat Schwann cells. *Biochem.Biophys.Res.Commun.*, **320**, 241-248.  
24  
25  
26 Somjee,S.S., Warriar,R.P., Thomson,J.L., Ory-Ascani,J., & Hempe,J.M. (2005) Advanced  
27 glycation end-products in sickle cell anaemia. *Br.J.Haematol.*, **128**, 112-118.  
28  
29  
30 Soro-Paavonen,A., Zhang,W.Z., Venardos,K., Coughlan,M.T., Harris,E., Tong,D.C.,  
31 Brasacchio,D., Paavonen,K., Chin-Dusting,J., Cooper,M.E., Kaye,D., Thomas,M.C.,  
32 & Forbes,J.M. (2010) Advanced glycation end-products induce vascular dysfunction  
33 via resistance to nitric oxide and suppression of endothelial nitric oxide synthase.  
34 *J.Hypertens.*  
35  
36  
37 Tatum,V.L. & Chow,C.K. (1996) Antioxidant status and susceptibility of sickle erythrocytes  
38 to oxidative and osmotic stress. *Free Radic.Res.*, **25**, 133-139.  
39  
40  
41 Teerlink,T., Barto,R., Ten Brink,H.J., & Schalkwijk,C.G. (2004) Measurement of Nepsilon-  
42 (carboxymethyl)lysine and Nepsilon-(carboxyethyl)lysine in human plasma protein by  
43 stable-isotope-dilution tandem mass spectrometry. *Clin.Chem.*, **50**, 1222-1228.  
44  
45  
46 van Beers,E.J., van Tuijn,C.F., Mac Gillavry,M.R., van der,G.A., Schnog,J.J., & Biemond,B.J.  
47 (2008) Sickle cell disease-related organ damage occurs irrespective of pain rate:  
48 implications for clinical practice. *Haematologica.*, **93**, 757-760.  
49  
50  
51 van Beijnum,J.R., Buurman,W.A., & Griffioen,A.W. (2008) Convergence and amplification  
52 of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE)  
53 signaling pathways via high mobility group B1 (HMGB1). *Angiogenesis.*, **11**, 91-99.  
54  
55  
56 Viberti,G.C. (1983) Increased capillary permeability in diabetes mellitus and its relationship  
57 to microvascular angiopathy. *Am.J.Med.*, **75**, 81-84.  
58  
59  
60 Wetterstroem,N., Brewer,G.J., Warth,J.A., Mitchinson,A., & Near,K. (1984) Relationship of  
glutathione levels and Heinz body formation to irreversibly sickled cells in sickle cell  
anemia. *J.Lab Clin.Med.*, **103**, 589-596.

1  
2  
3 Yamagishi,S., Inagaki,Y., Okamoto,T., Amano,S., Koga,K., Takeuchi,M., & Makita,Z. (2002)  
4 Advanced glycation end product-induced apoptosis and overexpression of vascular  
5 endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured  
6 mesangial cells. *J.Biol.Chem.*, **277**, 20309-20315.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

Table 1. Baseline characteristics.

	Controls (n = 30)	Asymptomatic State		Painful Crisis	
		HbSC/HbSβ <sup>+</sup> (n = 42)	HbSS/HbSβ <sup>0</sup> (n = 60)	HbSC/HbSβ <sup>+</sup> (n = 8)	HbSS/HbSβ <sup>0</sup> (n = 27)
Age, y	39 (19 – 59)	30 (18 – 57)*	25 (18 – 57)*	25 (20 – 48)	25 (19 – 48)
Gender (male/female)	19/11	27/15	35/25	8/0	14/13
BMI (Kg/m <sup>2</sup> )	25.4 (23.4 – 27.2)	23.4 (21.4 – 28.2)	21.3 (19.4 – 24.0)*‡	21.3 (18.8 – 28.4)	22.7 (19.6 – 26.0)
Hb (mmol/L)	7.9 (7.5 – 8.6)	6.9 (6.6 – 7.3)*	5.5 (4.9 – 6.1)*‡	6.9 (6.6 – 7.1)*	5.2 (4.4 – 5.8)*‡
Leukocytes (10 <sup>12</sup> /L)	5.3 (4.4 – 6.8)	6.4 (5.0 – 8.4)*	9.8 (7.9 – 10.9)*‡	8.4 (6.4 – 10.2)*	11.9 (10.6 – 14.0)*‡†
Platelets (10 <sup>12</sup> /L)	244 (205 – 296)	209 (161 – 336)	371 (284 – 481)*‡	183 (127 – 236)	334 (282 – 394)*‡
LDH (U/L)	177 (153 – 202)	230 (183 – 260)*	383 (304 – 504)*‡	223 (198 – 398)*	460 (425 – 641)*‡†
sVCAM-1 (ng/mL)	413 (368 – 474)	777 (630 – 924)*	987 (782 – 1254)*‡	741 (592 – 1109)	946 (811 – 1434)

Hb haemoglobin; LDH lactate dehydrogenase. Numbers are medians with 25<sup>th</sup> and 75<sup>th</sup> percentiles, age expressed as medians with range.

\* Significantly different as compared to healthy controls ( $P < 0.05$ ).

‡ Significantly different as compared to HbSC/HbSβ<sup>+</sup> within one state ( $P < 0.05$ ).

† Significantly different as compared to asymptomatic state ( $P < 0.05$ ).

Table 2. Correlation analyses of plasma levels of pentosidine and CML with markers of haemolysis and HbF in 60 HbSS/HbS $\beta^0$ -thalassaemia patients in asymptomatic state.

	Pentosidine (nmol/L)		CML (nmol/L)	
	Spearman's rho	<i>P</i> -value	Spearman's rho	<i>P</i> -value
Haemoglobin (mmol/L)	-0.29	0.024	-0.33	0.009
Haematocrit (L/L)	-0.43	0.032	-0.43	0.030
Reticulocyte %	0.34	0.018	0.28	0.054
LDH (U/L)	0.26	0.048	0.40	0.002
HbF (%)	-0.33	0.012	-0.35	0.006

Spearman Rank correlation coefficient ( $r_s$ ) was used. CML N<sup>e</sup>-(carboxymethyl)lysine; LDH lactate dehydrogenase; HbF foetal haemoglobin

Table 3. Correlations between markers of endothelial activations (sVCAM-1 and vWF:Ag) and pentosidine and CML in 60 HbSS/HbS $\beta^0$ -thalassaemia patients in asymptomatic state.

	sVCAM-1 (ng/mL)				vWF:Ag (%)			
	Asymptomatic State		Painful Crisis		Asymptomatic State		Painful Crisis	
	Spearman's rho	<i>P</i> -value	Spearman's rho	<i>P</i> -value	Spearman's rho	<i>P</i> -value	Spearman's rho	<i>P</i> -value
Pentosidine (nmol/L)	0.27	0.035	0.45	0.020	0.28	0.032	0.36	0.074
CML (nmol/L)	0.28	0.031	0.56	0.002	Not related		Not related	

sVCAM-1 soluble vascular adhesion molecule-1, vWF:Ag von Willebrand antigen.

Spearman Rank correlation coefficient ( $r_s$ ) was used. CML N<sup>ε</sup>-(carboxymethyl)lysine.

## Legends to the figures

### Figure 1

**Plasma levels of AGEs in healthy controls (CTRL) and HbSC/HbS $\beta^+$  (SC) and HbSS/HbS $\beta^0$  (SS) patients during asymptomatic state (AS) and painful crisis (CR). (A)**

While pentosidine levels are higher in both HbSC/HbS $\beta^+$  (SC-AS; n = 42;  $P = 0.002$ ) and HbSS/HbS $\beta^0$  (SS-AS; n = 60;  $P < 0.0001$ ) patients during asymptomatic state than in healthy controls (n = 30), they do not increase further during painful crisis (SC-CR, n = 8 and SS-CR, n = 27 respectively). Within the patients during steady state, HbSS/HbS $\beta^0$  patients have higher pentosidine levels than HbSC/HbS $\beta^+$  patients ( $P < 0.0001$ ) (B) Levels of N<sup>ε</sup>-(carboxymethyl)lysine (CML) are comparable between healthy controls and asymptomatic state HbSC/HbS $\beta^+$  patients but significantly higher in asymptomatic state HbSS/HbS $\beta^0$  patients ( $P = 0.007$ ). Also CML is higher in steady state HbSS/HbS $\beta^0$  patients than steady state HbSC/HbS $\beta^+$  patients ( $P = 0.008$ ). (C) Plasma levels of N<sup>ε</sup>-(carboxyethyl)lysine (CEL) are comparable between healthy controls and sickle cell patients both during asymptomatic state and painful crisis. Note the interruptions in the scale on Y axes.

### Figure 2.

**Plasma levels of pentosidine and N<sup>ε</sup>-(carboxymethyl)lysine (CML) in association with haemolysis related complications. (A) Pentosidine levels are higher in sickle cell patients**

with 1, 2 and 3 or 4 haemolysis-related organ complications compared to patients without these complications ( $P = 0.004$ , Kruskal-Wallis test). (B) When divided in two groups of patients without and those with at least one haemolysis-related organ complication, plasma levels of pentosidine were significantly higher in the latter group. This applied both when the differences were analyzed across all sickle cell patients in asymptomatic state ( $P = 0.006$ ) and

1  
2  
3 when the differences were analyzed for HbSS/HbS $\beta^0$  patients alone ( $P = 0.004$ ). (C) CML  
4  
5 levels are higher in sickle cell patients with 1, 2 and 3 or 4 haemolysis-related organ  
6  
7 complications compared to patients without these complications ( $P = 0.044$ , Kruskal-Wallis  
8  
9 test). (D) Also when divided in two groups of patients without and those with at least one  
10  
11 haemolysis-related organ complication, plasma levels of CML were higher in the latter group,  
12  
13 though the differences were not statistically significant. Leg ulcers, pulmonary hypertension,  
14  
15 ischemic strokes, priapism, cholecystolithiasis and microalbuminuria were counted as  
16  
17 haemolysis-related complications of SCD. Note the interruptions in the scale on Y axes.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






Figure 1.

For Peer Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






Figure 2.